Sohm Inc. (SHMN) Fair Value & Analysis
Healthcare · US · Market cap $3.2M
Sohm Inc.
SHMN · US
Fair value as of: Jun 25, 2026
From 7 valuation models · updated 53 days ago
Share price −27.3% over the past month.
Below-average quality, screening 38% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 25, 2026.
How to read this chart
60‑month range $0.0004 – $0.0140 · the $0.0008 price screens below the $0.0011 fair value. Dashed = 300-day average. As of Jun 25, 2026.
Analysis
Sohm Inc. (SHMN) currently trades at $0.0008, while our model-based Fair Value estimate is $0.0011, implying the stock looks roughly 37.5% undervalued today. The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Sohm Inc. generated revenue of $1.3M at a net margin of -87.3%. Revenue declined 45.2% year over year. Net debt stands at $2.6M. Fundamentals as of Jun 25, 2026
The share trades about 62% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 38%, SHMN screens cheaper than that median.
Notify me when SHMN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. The company offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. It also exports its products.
Full company description
SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. The company offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. It also exports its products. The company has collaboration agreement with Coastar Therapeutics to advance in the field of genome editing using red blood cell membrane derived carriers and genome editing technology. SOHM, Inc. was founded in 2005 and is based in Corona, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sohm Inc. reported revenue of $1.2M in FY2025 versus $325K in FY2021, a compound +38.0%/yr. Reported net income was −$506K in FY2025.
Watch SHMN: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Sohm Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sohm Inc. (SHMN) overvalued or undervalued?
What is the fair value of SHMN?
What is the quality score of SHMN?
What is the revenue of Sohm Inc. (SHMN)?
What is the net profit margin of SHMN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sohm Inc. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.